临床实验室之质谱分析

临床实验室之质谱分析 是由出版商Trimark Publications在2011年11月所出版的。 这份英文市场调查报告书包含165 Pages 价格从美金3400起跳。

简介

本报告为，详细分析质谱药物测试市场，并汇整市场规模、成长展望、技术平台、临床应用、新设备、产业趋势、欧美及日本为中心之地区别趋势等，以下列摘要形式阐述。

第1章 概要

第2章 临床实验室之质谱药物测试分析简介

• 临床实验室质谱分析测试及仪器
• 质谱分析设备概要
  • 质谱分析之临床应用
    • 治疗药物监测
    • 代谢性疾病
    • 内分泌
    • 临床毒性
    • 蛋白质组学
    • 生物标志物
• 质谱分析及临床诊断之机会
• 质谱分析测试市场之发展
• 质谱分析技术之进步

第3章 质谱分析测试市场

• 市场概要
• 质谱分析诊断市场
• 质谱分析临床测试平台

第4章 临床实验室之质谱分析诊断测试

• 使用质谱分析之临床实验室分子测试
• 主要检测
  • 药物滥用
  • 治疗药物
  • 激素分析
  • 新生儿筛选
• 质谱分析临床诊断之挑战
• 质谱分析扩大新的应用领域
  • 微生物学
  • 代谢
  • 癌症治疗
  • 免疫抑制剂
  • 疼痛管理药物
• 质谱分析市场之范式转换
• 代谢蛋白质组学自动化工作站生物标志物
• 多重化
• 使用质谱分析于生物标志之药物发现
• 技术进步／创新

第5章 临床实验室之质谱分析商业环境

• 技术及市场趋势
• M&A活动
• 合作
• 竞合分析
• 质谱分析临床产品之成功
• 智能财产权
• 机会及策略性建议
• 质谱分析临床产品之商业模式

第6章 产品开发／竞合环境

• 全球分析仪器制造商之决策
• 设备采用

第7章 使用临床实验室测试领域质谱分析平台时之商业决策、策略展望、建议

第8章 企业简介

• AB SCIEX
• Agilent Technologies
• Applied Biosystems/Sciex
• bioMerieux
• Bruker
• Danaher Corporation
• Hiden Analytical
• JEOL
• Konica Minolta
• MDS Analytical Technologies
• PerkinElmer
• 岛津制作所
• Spectro
• Thermo Fisher Scientific
• Varian
• Waters Corporation

图表

目录

Mass spectroscopy is a clinical laboratory analysis technique used in determining the basic composition and structure of a sample or molecule. The process involves bending a charged beam of vaporized material using an electric and/or magnetic field and then plotting a spectrum of how the sample's ions are deflected. Mass spectroscopy assays based on well-documented techniques such as time-of-flight, liquid chromatography/tandem, liquid chromatography, gas chromatography-quadrupole and others have gained wide acceptance in the clinical laboratory due to their accuracy, speed and sensitivity compared to traditional analytical drug detection techniques. This TriMark Publications report provides a detailed analysis of the mass spectroscopy drug testing market, including size, growth, technology platforms, clinical applications, new instrumentation, industry trends and the internal structure of the sector. The mass spectroscopy market remains the fastest-growing segment of the diagnostics analytical instruments market. Highly-attractive clinical growth areas covered in this study include: disease markers; molecular diagnostics; infectious disease; toxicology; inborn errors in metabolism; metabolomics; proteins and peptides; small molecule analytes (vitamins, steroids, thyroid, etc.); tobacco exposure; chemical warfare agents; tissue analysis by MALDI; clinical chemistry/toxicology; microbiology/virology; proteomic, metabolomic and tissue histology laboratories; high-end MS; and food testing. Also provided in this review is a thorough analysis of the companies known to be marketing, manufacturing or developing mass spectroscopy products in the U.S. and worldwide, as well as detailed tables, charts and figures with past and projected data analyzed by geographic region with a focus on the U.S., Europe and Japan, the world's three largest mass spectroscopy markets.

The senior author of this report holds a Ph.D. in biochemistry from the University of Minnesota, with many decades of experience in science writing and as a medical industry analyst. He has over 40 years of experience as a director in laboratory testing and instrument and reagent development technology, as well as extensive experience in senior level positions in biotech and medical service companies. The contributing analyst has a Ph.D. in chemistry from the University of Illinois, with more than 30 years of experience as a clinical laboratory director, as well as editing and writing articles in science and technology. He is currently laboratory director of a large urban hospital whose lab specializes in mass spectroscopy and drug analysis. Company-specific information is obtained mainly from industry trade publications, academic journals, news and research articles, press releases and corporate websites, as well as annual reports for publicly-held firms. Additional sources of information include non-governmental organizations (NGOs) such as the World Health Organization (WHO) and governmental entities such as the U.S. Department of Health and Human Services (HHS), the National Institutes of Health (NIH), the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Where possible and practicable, the most recent data available have been used.

Some of the statistical information was taken from Biotechnology Associates' database and from TriMark's private data stores. The information in this study was obtained from sources that we believe to be reliable, but we do not guarantee the accuracy, adequacy or completeness of any information or omission or for the results obtained by the use of such information. Key information from the business literature was used as a basis to conduct dialogue with and obtain expert opinion from market professionals regarding commercial potential and market sizes. Senior managers from major company players were interviewed for part of the information in this report. Primary Sources

1. Overview

• 1.1. Statement of Report
• 1.2. About This Report
• 1.3. Scope of the Report
• 1.4. Objectives
• 1.5. Methodology
• 1.6. Executive Summary

2. Introduction to Mass Spectroscopy for Clinical Laboratory Testing

• 2.1. Mass Spectroscopy Testing and Opportunities in the Clinical Laboratory Sector
• 2.2. Overview of Laboratory Mass Spectroscopy Instrumentation
  • 2.2.1. Clinical Applications of Mass Spectrometry
    • 2.2.1.1. Therapeutic Drug Monitoring
    • 2.2.1.2. Metabolic Diseases
    • 2.2.1.3. Endocrinology
    • 2.2.1.4. Clinical Toxicology
    • 2.2.1.5. Proteomics
    • 2.2.1.6. Biomarkers
• 2.3. Opportunities in Mass Spectroscopy and Clinical Diagnostics
• 2.4. Development of Mass Spectroscopy Testing Markets
• 2.5. Mass Spectrometry
  • 2.5.1. Overview of Mass Spectrometry
  • 2.5.2. Sample Introduction Techniques
  • 2.5.3. Ionization Source
    • 2.5.3.1. Electrospray Ionization
    • 2.5.3.2. Electron Ionization
    • 2.5.3.3. Matrix-Assisted Laser Desorption/Ionization (MALDI)
  • 2.5.4. Mass Analyzers
    • 2.5.4.1. Quadrupoles
    • 2.5.4.2. Quadrupole Ion Trap
    • 2.5.4.3. Linear Ion Trap
    • 2.5.4.4. Quadrupole Time-of-Flight Tandem MS (TOF)
    • 2.5.4.5. MALDI with Time-of-Flight Analysis (MALDI-TOF)
    • 2.5.4.6. Quadrupole Time-of-Flight MS
    • 2.5.4.7. Fourier Transform Mass Spectrometry (FTMS)
  • 2.5.5. Ion Detectors
• 2.6. Advances in Mass Spectroscopy Technologies
  • 2.6.1. Market Drivers and Restraints
    • 2.6.1.1. Market Drivers
    • 2.6.1.2. Market Restraints
  • 2.6.2. Market and Technology Trends
    • 2.6.2.1. Market Trends
    • 2.6.2 2. Technology Trends
  • 2.6.3. Strategic Recommendations

3. Mass Spectroscopy Diagnostics Testing Market

• 3.1. Market Overview
  • 3.1.1. Overall Mass Spectroscopy Clinical Laboratory Market Analysis
• 3.2. Mass Spectroscopy Diagnostics Market
• 3.3. Mass Spectroscopy Clinical Testing Platforms
  • 3.3.1. Gas Chromatography/Mass Spectrometry (GC/MS)
    • 3.3.1.1. Background
    • 3.3.1.2. Instruments
    • 3.3.1.3. Method Comparisons
    • 3.3.1.4. Market Drivers and Restraints
      • 3.3.1.4.1. Market Drivers
      • 3.3.1.4.2. Market Restraints
    • 3.3.1.5. Market and Technology Trends
      • 3.3.1.5.1. Market Trends
      • 3.3.1.5.2. Technology Trends
      • 3.3.1.5.3. Strategic Recommendations
  • 3.3.2. Ion Trap and Quadrupole Mass Spectrometers
    • 3.3.2.1. Background
      • 3.3.2.1.1. Instruments
      • 3.3.2.1.2. Method Comparisons
      • 3.3.2.1.3. Market Challenges and Strategic Recommendations
        • 3.3.2.1.3.1. Market Drivers and Restraints
          • 3.3.2.1.3.1.1. Market Drivers
          • 3.3.2.1.3.1.2. Market Restraints
      • 3.3.2.1.4. Market and Technology Trends
        • 3.3.2.1.4.1. Market Trends
        • 3.3.2.1.4.2. Technology Trends
      • 3.3.2.1.5. Strategic Recommendations
  • 3.3.3. Liquid Chromatography/Mass Spectrometry
    • 3.3.3.1. Background
    • 3.3.3.2. Instruments
    • 3.3.3.3. Method Comparisons
    • 3.3.3.4. Market Size
      • 3.3.3.4.1. Liquid Chromatography/Mass Spectroscopy (LC/MS) Market Size
        • 3.3.3.4.1.1. Market Share
      • 3.3.3.4.2. Market Challenges and Strategic Recommendations
        • 3.3.3.4.2.1. Market Drivers and Restraints
          • 3.3.3.4.2.1.1. Market Drivers
          • 3.3.3.4.2.1.2. Market Restraints
      • 3.3.3.4.3. Market and Technology Trends
        • 3.3.3.4.3.1. Market Trends
        • 3.3.3.4.3.2. Technology Trends
      • 3.3.3.4.4. Strategic Recommendations
  • 3.3.4. Ion Mobility and High Definition Mass Spectrometry
    • 3.3.4.1. Background
  • 3.3.5. Liquid Chromatography Tandem Mass Spectrometry
    • 3.3.5.1. Background
  • 3.3.6. Time-of-Flight Mass Spectrometry
    • 3.3.6.1. Background
  • 3.3.7. Orbitrap
    • 3.3.7.1. Background
    • 3.3.7.2. Instruments
    • 3.3.7.3. Method Comparisons
    • 3.3.7.4. Market and Technology Trends
      • 3.3.7.4.1. Market Trends
      • 3.3.7.4.2. Technology Trends
      • 3.3.7.4.3. Strategic Recommendations
  • 3.3.8. Matrix-Assisted Laser Desorption/Ionization (MALDI) Time-of-Flight Mass Spectrometry
    • 3.3.8.1. Background
  • 3.3.9. Inductively coupled Plasma Mass Spectrometry (ICP)
    • 3.3.9.1. Background
    • 3.3.9.2. Instruments
    • 3.3.9.3. Method Comparisons
  • 3.3.10. FTMS

4. Mass Spectrometry Diagnostic Testing in the Clinical Laboratory

• 4.1. Clinical Laboratory Molecular Tests Using Mass Spectroscopy
• 4.2. Top Mass Spectroscopy Assays
  • 4.2.1. Drugs of Abuse
  • 4.2.2. Therapeutic Drugs
  • 4.2.3. Hormone Analysis
    • 4.2.3.1. Vitamin D
    • 4.2.3.2. Testosterone and Estradiol
    • 4.2.3.3. Other Hormones
  • 4.2.4. Newborn Screening
• 4.3. Challenges in Mass Spectrometry Clinical Diagnostic Technologies
  • 4.3.1. Market Drivers and Restraints
    • 4.3.1.1. Market Drivers
    • 4.3.1.2. Market Restraints
  • 4.3.2. Market and Technology Trends
    • 4.3.2.1. Market Trends
    • 4.3.2.2. Technology Trends
  • 4.3.3. Strategic Recommendations
  • 4.3.4. Cost of Mass Spectroscopy Testing
  • 4.3.5. Priorities for Vendors
  • 4.3.6. Mass Spectrometers Market Continues to Grow
• 4.4. Mass Spectroscopy Develops Novel Applications
  • 4.4.1. Microbiology
  • 4.4.2. Metabolomics
  • 4.4.3. Cancer Therapy
  • 4.4.4. Immunosuppressant Drugs
  • 4.4.5. Pain Management Drugs
• 4.5. Paradigm Shift within the Mass Spectrometry Market
• 4.6. Metabolomics
• 4.7. Proteomics
• 4.8. Automated Workstations
• 4.9. Biomarkers
• 4.10. Multiplexing
• 4.11. Use of Mass Spectrometry in Biomarker Discovery
  • 4.11.1. Multiple Reaction Monitoring Assays (MRMs)
  • 4.11.2. Gel-based Approaches
  • 4.11.3. Non-Gel-based Approaches
  • 4.11.4. SELDI-TOF MS
  • 4.11.5. SELDI and Prognosis
  • 4.11.6. SELDI and Treatment Monitoring
  • 4.11.7. Limitations of Mass Spectroscopy
• 4.12. Technological Breakthroughs/Innovations
  • 4.12.1. Hybrids
  • 4.12.2. Integrated and Hybrid-based MS systems
  • 4.12.3. LTQ-Velos
  • 4.12.4. Applied Biosystems Integrates Two MS technologies
  • 4.12.5. Q-TOF-MS Leads
  • 4.12.6 Agilent
  • 4.12.6 Agilent?s Chip LC/MS Systems
  • 4.12.7 New Virus Detection System Based on Mass Spectrometry
  • 4.12.8 Orbitrap MS System
  • 4.12.9 Qual-Quan Mass Spectroscopy
  • 4.12.10 SISCAPA
  • 4.12.11 SRM/MRM
  • 4.12.12 AB Sciex?s iMethod and Cliquid Software
  • 4.12.13 Microsaic Mini Mass Specs

5. Business Landscape for Mass Spectroscopy for Clinical Labs

• 5.1. Technology and Market Trends
  • 5.1.1. Market Trends
  • 5.1.2. Technology Trends
• 5.2. M&A Activity
• 5.3. Partnerships
• 5.4. Competitive Analysis
  • 5.4.1. Primary Competitors
  • 5.4.2. Industry Challenges and Strategic Recommendations
  • 5.4.3. Commercialization of Mass Spectroscopy Products
• 5.5. The Success Achieved by the Mass Spectroscopy Clinical Products
• 5.6. Intellectual Property Rights
  • 5.6.1. New Patents
  • 5.6.2. Current Patent Disputes
• 5.7. Opportunities and Strategic Recommendations
  • 5.7.1. Key Technical Opportunities with Significant Market Appeal in the Mass Spectroscopy Space in the Next Five Years
  • 5.7.2. Developments for Mass Spectroscopy Instrumentation Products
  • 5.7.3. Market Penetration Strategies for Clinical Laboratory Testing
• 5.8. Business Models in Mass Spectroscopy Clinical Products
  • 5.8.1. Scope of This Section
  • 5.8.2. Business Models for Clinical Mass Spectroscopy Markets
    • 5.8.2.1. SWOT Comparison of Business Models for Mass Spectrometry Diagnostic Testing
  • 5.8.3. Sales and Marketing Strategies for Clinical Laboratory Tests

6. Product Developments/Competitive Landscape

• 6.1. Manufacturers Decisions in the Global Analytical Instrument Industry
• 6.2. Instrument Introductions

7. Business Decisions, Strategic Outlook and Recommendations Using Mass Spectroscopy Technology Platforms in the Clinical Laboratory Testing Space

• 7.1. What are the Key Opportunities for Mass Spectroscopy in Clinical Laboratory Testing Development and Commercialization?
• 7.2. What are the Current Obstacles for Mass Spectroscopy in Clinical Laboratory Testing Implementation?
• 7.3. How Do Business Strategies, Such as those Relating to Acquisition, Drive Mass Spectroscopy Strategies?
• 7.4. How Might Novel Clinical Laboratory MS Test Development Lead to Acquisition or Partnering Strategies and their Implications for Deal Making?
• 7.5. How can Mass Spectroscopy Tests Increase Value in an Associated Drug Marketing Plan?
• 7.6. Which Types of Clinical Laboratory Testing Should be Developed by Mass Spectroscopy Companies?
• 7.7. How can Regulatory Oversight Drive Approval and Adoption of New Technologies?
• 7.8. What are the Noteworthy Deals?
• 7.9. Who are the Acquirers?
• 7.10. Who are the Target Companies?
• 7.11. How will Platform Technology Companies Enter the Space?
• 7.12. Will Pharma Integrate with Diagnostics?
• 7.13. How Do Platform Technology Companies Position Themselves for Diagnostic and Pharma Development?
• 7.14. Evaluate How Partnering and M&As will Alter the Competitive Landscape
• 7.15. Predict How FDA Regs will Impact New Diagnostic Tests
• 7.16. How can Big Pharma and Mass Spectroscopy Companies Co-develop Biomarkers in a Model for Regulatory Acceptance?
• 7.17. How to Maximize Business Development through Biomarker Strategies?
• 7.18. What is the Best Type of Business Model for Developing Genetic Biomarkers for Clinical Laboratory?
• 7.19. How Best can Mass Spectroscopy Provide the Most Benefit in Clinical Laboratory Testing?
• 7.20. What are the Most Innovative Methods in Development of Mass Spectroscopy Diagnostic Testing?

8. Company Profiles

• 8.1. AB SCIEX
• 8.2. Agilent Technologies
• 8.3. Applied Biosystems/Sciex
• 8.4. bioMerieux
• 8.5. Bruker
• 8.6. Danaher Corporation
• 8.7. Hiden Analytical
• 8.8. JEOL
• 8.9. Konica Minolta
• 8.10. MDS Analytical Technologies
• 8.11. PerkinElmer
• 8.12. Shimadzu Corporation
• 8.13. Spectro
• 8.14. Thermo Fisher Scientific
• 8.15. Varian
• 8.16. Waters Corporation

• Figure 2.1: Relationship of Mass Spectrometry Testing to Key Areas of Clinical Diagnosis
• Figure 2.2: Magnetic or Electrostatic Sector in Mass Spectroscopy
• Figure 2.3: Triple Quadrupole (Tandem) Mass Spectroscopy
• Figure 2.4: Time-of-flight Mass Spectroscopy
• Figure 2.5: Diagram of a Quadrupole MS Analyzer
• Figure 2.6: Diagram of an Ion Trap MS Analyzer
• Figure 3.1: Mass Spectroscopy by Testing Type, 2010
• Figure 3.2: Key Players Market Share in Global Mass Spectroscopy Testing Market
• Figure 3.3: Mass Spectroscopy World Market and Global Testing for Forensic and Drug Testing, 2007-2010
• Figure 3.4: Global Revenue Forecast for Mass Spectroscopy, 2009-2016
• Figure 3.5: Global Market Revenue Share Forecast for Mass Spectroscopy Testing Markets by Region, 2010 and 2016
• Figure 3.6: U.S. Market Revenue Forecast for Mass Spectroscopy, 2009-2016
• Figure 3.7: European Market Revenue Forecast for Mass Spectroscopy, 2009-2016
• Figure 3.8: Japanese Market Revenue Forecast for Mass Spectroscopy, 2009-2016
• Figure 3.9: Global Revenue Forecast for Mass Spectroscopy Forensic and Drug Testing Market, 2009-2016
• Figure 3.10: Global Market Revenue Share Forecast for Mass Spectroscopy Forensic and Drug Testing Markets by Region, 2010 and 2016
• Figure 3.11: U.S. Market Revenue Forecast for Mass Spectroscopy Forensic and Drug Testing Market, 2009-2016
• Figure 3.12: European Market Revenue Forecast for Mass Spectroscopy Forensic and Drug Testing Market, 2009-2015
• Figure 3.13: Japanese Market Revenue Forecast for Mass Spectroscopy Forensic and Drug Testing Market, 2009-2016
• Figure 3.14: Mass Spectrometry Supplier Market Shares
• Figure 5.1: Market Growth of MS Clinical Laboratory Tests
• Figure 8.1: Agilent?s Well Distributed Worldwide Business
• Figure 8.2: Bruker?s Revenue Stream
• Figure 8.3: Bruker?s Geographic Distribution
• Figure 8.4: Thermo Fisher Laboratory Products Revenue Share
• Figure 8.5: Thermo Fisher Biosciences Revenue Shares

• Table 2.1: Mass Spectrometry Utilization in the Clinical and Life Science Space
• Table 2.2: Mass Spectrometry Tests for Clinical Applications
• Table 2.3: Emerging Mass Spectrometric Technologies
• Table 2.4: Advantages of Electrospray Ionization (ESI)
• Table 2.5: Disadvantages of Electrospray Ionization (ESI)
• Table 2.6: Advantages of Matrix-Assisted Laser Desorption/Ionization (MALDI)
• Table 2.7: Disadvantages of Matrix-Assisted Laser Desorption/Ionization (MALDI)
• Table 2.8: Mass Analyzers Event
• Table 2.9: Automated Mass Spectroscopy Platforms for Clinical Laboratory Testing
• Table 2.10: Companies Marketing Products Using MS Technology Platforms
• Table 2.11: Mass Spectroscopy Market: Market Drivers Ranked in Order of Impact
• Table 2.12: Mass Spectroscopy Market: Market Restraints Ranked in Order of Impact
• Table 2.13: A Timeline of Mass Spectrometry
• Table 2.14: Attractive Growth Areas for Mass Spectroscopy Testing
• Table 3.1: Mass Spectroscopy World Market, 2007-2010
• Table 3.2: Mass Spectroscopy U.S. Market, 2007-2010
• Table 3.3: Mass Spectroscopy European Market, 2007-2010
• Table 3.4: Mass Spectroscopy Japan Market, 2007-2010
• Table 3.5: Mass Spectroscopy Global Testing Sectors for Forensic and Drug Testing Market, 2007-2010
• Table 3.6: Mass Spectroscopy U.S. Testing Sectors for Forensic and Drug Testing Market, 2007-2010
• Table 3.7: Mass Spectroscopy European Testing Sectors for Forensic and Drug Testing Market, 2007-2010
• Table 3.8: Mass Spectroscopy Japanese Testing Sectors for Forensic and Drug Testing Market, 2007-2010
• Table 3.9: Share of Mass Spectroscopy Testing for Life Science, Pharma, and Clinical by Testing Type, 2010
• Table 3.10: Key Players and Market Share in Global Mass Spectroscopy Testing Market
• Table 3.11: Revenue Model for Mass Spectrometry Testing
• Table 3.12: Mass Spectroscopy in the Clinical Market: Market Drivers Ranked in Order of Impact
• Table 3.13: Mass Spectroscopy in the Clinical Market: Market Restraints Ranked in Order of Impact
• Table 3.14: Global Revenue Forecast for Mass Spectroscopy, 2009-2016
• Table 3.15: U.S. Market Revenue Forecast for Mass Spectroscopy, 2009-2016
• Table 3.16: European Market Revenue Forecast for Mass Spectroscopy, 2009-2016
• Table 3.17: Japanese Market Revenue Forecast for Mass Spectroscopy, 2009-2016
• Table 3.18: Global Revenue Forecast for Mass Spectroscopy Forensic and Drug Testing Market, 2009-2016
• Table 3.19: U.S. Market Revenue Forecast for Mass Spectroscopy Forensic and Drug Testing Market, 2009-2016
• Table 3.20: European Market Revenue Forecast for Mass Spectroscopy Forensic and Drug Testing Market, 2009-2015
• Table 3.21: Japanese Market Revenue Forecast for Mass Spectroscopy Forensic and Drug Testing Market, 2009-2016
• Table 3.22: Business Factors Influencing Advanced Mass Spectroscopy Testing Services
• Table 3.23: Companies Marketing Multiple Products in Mass Spectroscopy Sector
• Table 3.24: Commercially Available GC/MS Spectrophotometers
• Table 3.25: GC/MS Market: Market Drivers Ranked in Order of Impact
• Table 3.26: GC/MS Market: Market Restraints Ranked in Order of Impact
• Table 3.27: Commercially Available Ion Trap MS
• Table 3.28: Commercially Available Liquid Chromatography/MS Systems
• Table 3.29: Commercially Available Orbitrap MS
• Table 3.30: Commercially Available MALDI MS
• Table 3.31: Commercially Available ICP MS
• Table 4.1: Immunoassays vs. Liquid Chromatography/Mass Spectrometry for Clinical Analysis
• Table 4.2: Drugs-of-Abuse and Pain Management
• Table 4.3: Fastest-Growing Lab Tests, 2006-2009
• Table 4.4: Therapeutic Drugs
• Table 4.5: Utilization of Mass Spectrometry for Hormone Analysis
• Table 4.6: Steroids Commonly Measured Using MS Technology Platforms
• Table 4.7: Mass Spectroscopy Newborn Screening Program
• Table 4.8: Prevalence of Metabolic Disorders Analyzed by MS/MS
• Table 4.9: Principal Cost Factors in the Mass Spectroscopy Clinical Laboratory Testing Market
• Table 4.10: Priorities for Vendors
• Table 4.11: Key Drivers of the Mass Spectroscopy Market in Life Sciences
• Table 4.12: Proteins Measured in Clinically-available MS Tests in the U.S.
• Table 4.13: Concentration of Some Abundant Proteins, New Cancer Biomarkers Identified by SELDI-TOF, and Classical Cancer Biomarkers in Serum
• Table 4.14: Strengths and Limitations of MRM Assays
• Table 4.15: Software Methods for Mass Spectroscopy for Clinical Analysis
• Table 4.16: Software Methods for Mass Spectroscopy for Drugs of Abuse Analysis
• Table 5.1: Technology Trends in Mass Spectroscopy for Clinical Laboratory Testing
• Table 5.2: Clinical Testing Trends in Mass Spectroscopy for Clinical Laboratory Testing
• Table 5.3: Business Market Trends in Mass Spectroscopy Clinical Laboratory Testing
• Table 5.4: Expected Changes in Healthcare
• Table 5.5: Customer Feedback for Automated Mass Spectroscopy Instruments
• Table 5.6: Mass Spectroscopy Clinical Laboratory Market: Market Drivers Ranked in Order of Impact
• Table 5.7: Mass Spectroscopy Clinical Laboratory Market: Market Restraints Ranked in Order of Impact
• Table 5.8: Advantages of European Markets for Mass Spectroscopy Testing
• Table 5.9: Disadvantages of European Markets for Mass Spectroscopy Testing
• Table 5.10: Summary of Recent M&A Activity in the Mass Spectroscopy Sector
• Table 5.11: High Value Opportunities in Collaborative and Strategic Partnerships Using MS
• Table 5.12: Principal Competitive Factors in the Mass Spectroscopy Clinical Laboratory Testing Market
• Table 5.13: Mass Spectroscopy Clinical Laboratory Testing Market: Strategic Recommendations on Mass spectroscopy Sector Business Functions
• Table 5.14: Mass Spectroscopy Clinical Laboratory Market: Impact of Top Industry Challenges (U.S.)
• Table 5.15: Documents for Protecting Intellectual Property Rights
• Table 5.16: Specific Opportunities for Automated Instrumentation and Reagent Systems in Mass Spectroscopy for Clinical Laboratory Testing
• Table 5.17: Strategies and POA for Marketing Clinical Laboratory Diagnostic Products
• Table 7.1: Effect of Regulation on Molecular Diagnostics Clinical Laboratory Market Technology Platforms, 2007-2015
• Table 7.2: Companies Utilizing New, Cutting-Edge Technologies to Develop, Validate and Market Mass Spectroscopy Tests for Clinical Use
• Table 7.3: Impediments to Incorporating Promising Mass Spectroscopy Tests into Clinical Practice
• Table 7.4: Alliances Showing the Greatest Synergy in Bringing Mass Spectroscopy?s Tests to Market

相关商品

Trimark Publications发行的医疗设备相关市场调查报告书

个性化医疗与癌症治疗上的搭配诊断

Companion Diagnostics in Personalized Medicine and Cancer Therapy

价格 : US $ 3400

出版日期 : 2012年02月

血糖值检验及糖尿病管理

Blood Glucose Testing and Diabetes Management

价格 : US $ 3400

出版日期 : 2012年02月

全球医护站诊断检验市场

Point of Care Diagnostic Testing World Markets

价格 : US $ 3400

出版日期 : 2012年02月

Email Alert(Email 通知) - 最新市场调查报告书

GII 将每天定期更新最新市场调查报书信息，选择您有兴趣的市场分类，我们将用Email的方式让您收到最新讯息!